Long-acting polypeptides and methods of producing and administering same
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
1. A polypeptide consisting of a glucagon-like peptide 1 (GLP-1) peptide of interest, and three chorionic gonadotropin carboxy terminal peptides attached to said peptide of interest and optionally a signal peptide, wherein a first chorionic gonadotropin carboxy terminal peptide is attached to an amino terminus of said peptide of interest, a second chorionic gonadotropin carboxy terminal peptide is attached to a carboxy terminus of said peptide of interest, and a third chorionic gonadotrophin carboxy terminal peptide is attached in tandem to said second chorionic gonadotropin carboxy terminal peptide, wherein the amino acid sequence of said peptide of interest consists of SEQ ID NO: 25.
2. The polypeptide of claim 1 , wherein the sequence of at least one of said chorionic gonadotropin carboxy terminal peptides consists of an amino acid sequence selected from sequences set forth in SEQ ID NO: 17 and SEQ ID NO: 18.
3. The polypeptide of claim 1 , wherein at least one of said chorionic gonadotropin carboxy terminal peptides is truncated.
4. The polypeptide of claim 1 , wherein said peptide of interest is glycosylated.
5. The polypeptide of claim 1 , wherein said peptide of interest is non-glycosylated.
6. The polypeptide of claim 1 , wherein at least one of said chorionic gonadotropin carboxy terminal peptides is glycosylated.
7. The polypeptide of claim 1 , wherein at least one of said chorionic gonadotropin carboxy terminal peptides is attached to said peptide of interest via a linker.
8. The polypeptide of claim 7 , wherein said linker is a peptide bond.
9. The polypeptide of claim 1 , wherein when said optional signal peptide is present, the amino acid sequence of said signal peptide is as set forth in SEQ ID NO: 19 or SEQ ID NO: 26.
10. A pharmaceutical formulation comprising the polypeptide of claim 1 , wherein said formulation further comprises a buffer, and a tonicity agent.
11. The formulation of claim 10 , wherein said buffer is citrate or acetate.
12. The formulation of claim 10 , wherein said tonicity agent is sodium chloride.
13. The formulation of claim 10 , wherein said formulation is formulated for injection in a multidose container, with optionally, a preservative.
14. The formulation of claim 13 , wherein said preservative is benzalkonium chloride or thimerosal.
15. A liquid formulation, comprising the formulation of claim 14 .
16. The liquid formulation of claim 15 , wherein said formulation is at a pH between about 6 to 7.
17. The polypeptide of claim 1 , wherein said GLP-1 peptide has insulinotropic activity.
18. A method of improving a biological half life of a glucagon-like peptide 1 (GLP-1) peptide of interest, comprising the step of attaching three chorionic gonadotropin carboxy terminal peptides to said peptide of interest, wherein a first chorionic gonadotropin carboxy terminal peptide is attached to an amino terminus of said peptide of interest, a second chorionic gonadotropin carboxy terminal is attached to a carboxy terminus of said peptide of interest, and a third chorionic gonadotrophin carboxy terminal peptide is attached in tandem to said second chorionic gonadotropin carboxy terminal peptide, wherein the amino acid sequence of said peptide of interest consists of SEQ ID NO: 25, and wherein optionally a signal peptide is attached at the N-terminal end of the first chorionic gonadotropin carboxy terminal peptide, thereby improving a biological half life of a peptide of interest.
19. The method of claim 18 , wherein the sequence of at least one of said three chorionic gonadotropin carboxy terminal peptides consists of an amino acid sequence selected from the sequences set forth in SEQ ID NO: 17-18.